Evidence mapPaperPMID 34889142Full record

ReviewJournal of diabetes science and technology2023

Needle Technology for Insulin Administration: A Century of Innovation.

Lutz Heinemann, Trung Nguyen, Timothy S Bailey, Ahmed Hassoun, Bernd Kulzer, Teresa Oliveria, Yves Reznik, Harold W de Valk, Julia K Mader

Abstract readReview
In one paragraph

Review in Journal of diabetes science and technology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Optimising Insulin Injection Techniques to Improve Diabetes Outcomes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023
    Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lutz HeinemannScience Consulting in Diabetes GmbH, Kaarst, Germany.ORCID 0000-0003-2493-1304
Trung NguyenBecton, Dickinson and Company, Eysins, Switzerland.ORCID 0000-0003-3169-2460
Timothy S BaileyAMCR Institute, Inc., Escondido, CA, USA.
Ahmed HassounDivision of Endocrinology, Department of Internal Medicine, Fakeeh University Hospital, Dubai, United Arab Emirates.
Bernd KulzerResearch Institute Diabetes Academy Mergentheim, Bad Mergentheim, Germany.
Teresa OliveriaBecton, Dickinson and Company, Eysins, Switzerland.
Yves ReznikDepartment of Endocrinology and Diabetology, CHU Côte de Nacre, Caen, France.
Harold W de ValkDepartment of Internal Medicine, University Medical Centre Utrecht, Utrecht, The Netherlands.
Julia K MaderDivision of Endocrinology & Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.ORCID 0000-0001-7854-4233

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Innovations in syringe and pen needle (PN) technology over the last 100 years have led to important advances in insulin delivery for people with diabetes, paralleling the strides made in developing recombinant DNA human insulin and insulin analogs with varying onset and duration of action. In this review, the history of advances in insulin delivery is described, focusing on progress in syringe, needle, and PN technologies. The early glass and metal syringes that required sterilization by boiling have been replaced by disposable, single-use syringes or pens with clear labeling for precise insulin dosing. The early needles ranging in length from 19 to 26 mm that required manual sharpening against a whetstone have been replaced by syringe needles of 6 mm and PNs of 4 mm in length as slender as 34 gauge. Imaging studies using ultrasound and computed tomography measured the thickness of skin and subcutaneous tissue layers to show feasibility of targeted insulin administration with shorter needles. These developments, coupled with innovations in needle/PN wall and tip structure, have led to improved injection experience for people with diabetes. It is also important to acknowledge the role of injection technique education, together with these advances in injection technology, for improving clinical outcomes and patient satisfaction. With continued projected growth of diabetes prevalence, particularly in developing countries where expensive and complex insulin delivery systems may not be practical, insulin syringes and pens will continue to serve as reliable and cost-effective means of insulin delivery for people with diabetes.

Indexed as

Diabetes MellitusInsulinHumansInjections, SubcutaneousInsulin, Regular, HumanPatient SatisfactionSkinInsulinInsulin, Regular, Humaninsulin administrationinsulin peninsulin therapyneedle lengthsubcutaneoussyringe

Identifiers

PMID34889142
PMCPMC10012366

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.